A 72-year-old man with a 5-year history of BPH presents with acute urinary retention. He was started on finasteride 6 months ago for a large prostate (50 g on ultrasound) and initially improved. However, over the past 3 weeks, he has had progressive hesitancy and weak stream. Tonight, he cannot void and has suprapubic pain. Catheterization yields 800 mL of clear urine. Post-catheterization, his serum creatinine is 1.8 mg/dL (baseline 1.0 mg/dL). What is the most likely reason for his acute decompensation?

Explanation

## Clinical Context & Pathophysiology This patient developed **acute urinary retention** despite 6 months of finasteride monotherapy for a large prostate (50 g). The key clinical clues are: - Large prostate volume (50 g) → high dynamic and static obstruction. - Finasteride alone → reduces prostate volume but does NOT relieve acute obstruction. - Progressive hesitancy and weak stream over 3 weeks → worsening outlet obstruction. - Acute retention with high post-void residual (800 mL). ## Medical Management Principles for Large BPH **Key Point:** In patients with large prostate glands (>40 g), combination therapy with α1-blocker + 5-alpha reductase inhibitor is superior to monotherapy. **High-Yield:** Mechanism of action differences: | Agent | Onset | Mechanism | Effect | |-------|-------|-----------|--------| | α1-blocker (tamsulosin) | 1–2 weeks | Blocks smooth muscle contraction in prostate capsule and bladder neck | Relieves dynamic obstruction immediately | | 5α-reductase inhibitor (finasteride) | 6–12 months | Inhibits DHT → reduces prostate volume | Reduces static obstruction (25% volume reduction) | | **Combination** | Weeks + months | Synergistic: immediate relief + long-term volume reduction | Prevents progression and acute retention | **Clinical Pearl:** Finasteride monotherapy in a 50 g prostate is inadequate because: 1. It takes 6–12 months to shrink the gland. 2. It does NOT address the **dynamic component** of obstruction (smooth muscle contraction). 3. Without an α1-blocker, the patient remains at risk for acute retention during the waiting period. ## Why Acute Retention Occurred The patient's large prostate created significant outlet obstruction. Finasteride alone could not: - Provide immediate symptom relief (requires α1-blocker). - Prevent acute decompensation during the slow volume reduction phase. - Overcome the dynamic obstruction component. Progressive hesitancy and weak stream over 3 weeks indicate worsening obstruction that finasteride monotherapy could not manage. **Mnemonic: BPH Combination Therapy** — **"FAST + SLOW"** - **FAST** = α1-blocker (immediate relief) - **SLOW** = 5α-reductase inhibitor (long-term volume reduction) ## Why Not the Other Options? **Finasteride-induced prostatitis:** Finasteride does not cause acute prostatitis. It is well-tolerated and does not induce inflammation. **Acute bacterial cystitis:** The urine is clear, and there is no mention of dysuria, frequency, or fever. The primary problem is outlet obstruction, not infection. **Prostatic carcinoma:** PSA was not mentioned as elevated, and the presentation is consistent with BPH progression, not malignancy. Carcinoma would not typically present with acute retention after 6 months of finasteride.